Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for two pharmaceutical deals announced in Q3 2024, worth a total value of $225.9m. The $220m investment by Shenzhen Luye Private Equity Investment Fund in Shenzhen Luye was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
Smarter leaders trust GlobalData
In value terms, orphan designated drugs-related deal activity increased by 468% in Q3 2024 compared with the previous quarter’s total of $39.8m and fell by 18% as compared to Q3 2023. Related deal volume decreased by 60% in Q3 2024 versus the previous quarter and was 50% lower than in Q3 2023.
The top-ranked legal advisors supporting these private equity deals in 9M 2024 were Kirkland & Ellis; Cooley; Latham & Watkins with 3, 2, 2 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.
